11 Result(s)

Article

A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

The objectives of this study were to characterize the population pharmacokinetics of MTX in patients with acute lymphoblastic leukemia (ALL) with ages ranging from 2 to 16 years and to propose a limited sampli...

Christine Piard, Françoise Bressolle, May Fakhoury… in Cancer Chemotherapy and Pharmacology (2007)

Article

Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen

Purpose: Irinotecan is extensively metabolized into at least four compounds and previous pharmacokinetic–pharmacodynamic studies have given varying results. We hypothesized that saliva, a...

Sylvain Poujol, Françoise Bressolle… in Cancer Chemotherapy and Pharmacology (2006)

Article

Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies

The objective of the present study was to characterize the population pharmacokinetics of melphalan infused over a 24-h period in patients with advanced malignancies.

Philippe Mougenot, Frédéric **uet, Michel Fabbro… in Cancer Chemotherapy and Pharmacology (2004)

Article

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen

The aim of this phase II study was to determine the efficacy and tolerability of the bimonthly, pharmacokinetically intensified LV5FU2 regimen in the treatment of metastatic colorectal cancers.

Marc Ychou, Jacqueline Duffour, Andrew Kramar… in Cancer Chemotherapy and Pharmacology (2003)

Article

Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer

Purpose: As vinorelbine is 78% bound to platelets, it seems interesting to investigate the pharmacokinetic profile of this drug from blood and to compare it to that determined from plasma. Thus, in this study, t...

Amélie Gauvin, Frédéric **uet, Stéphane Culine… in Cancer Chemotherapy and Pharmacology (2002)

Article

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

Purpose: The purpose of this work was to estimate the population pharmacokinetic parameters of 5-fluorouracil (5-FU) in patients with advanced colorectal cancer using circadian change kinetics. Methods: Eighty-f...

Françoise Bressolle, Jean M. Joulia… in Cancer Chemotherapy and Pharmacology (1999)

Article

Methyl-β-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin

The purpose of this work was to determine the role of methyl-β-cyclodextrin (MEBCD) in combination with doxorubicin (DOX) on the cellular proliferation of a sensitive parental and a multidrug-resistant human ...

Pierre-Yves Grosse, Françoise Bressolle… in Cancer Chemotherapy and Pharmacology (1997)

Article

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

Véronique Pinzani, Françoise Bressolle… in Cancer Chemotherapy and Pharmacology (1994)

Article

Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva

The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28–72 mg/m² DOX (nine courses). Plasma and parotid saliva wer...

Françoise Bressolle, Jeanne-Marie Jacquet… in Cancer Chemotherapy and Pharmacology (1992)

Article

Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters

Doxorubicin was given by short i. v. infusion (dose range 25–72 mg/m²) to 18 patients who underwent three to seven successive courses of chemotherapy (total, 57 courses). Plasma levels of doxorubicin and its majo...

Jeanne-Marie Jacquet, Françoise Bressolle… in Cancer Chemotherapy and Pharmacology (1990)